Currently, there is a phase 1 trial investigating anti-TIM3 (MBG453) in combination with spartalizumab (anti-PD1) in combination with SRS in recurrent GBM patients, however no results have been published to date (NCT03961971). The gene discussed is PDCD1; the disease is glioblastoma.